Prosecution Insights
Last updated: April 19, 2026

Examiner: SHIAO, YIH-HORNG

Tech Center 1600 • Art Units: 1621 1623 1672 1673 1691 1693

This examiner grants 72% of resolved cases

Performance Statistics

72.5%
Allow Rate
+12.5% vs TC avg
974
Total Applications
+75.9%
Interview Lift
959
Avg Prosecution Days
Based on 942 resolved cases, 2023–2026

Rejection Statute Breakdown

5.8%
§101 Eligibility
20.8%
§102 Novelty
31.3%
§103 Obviousness
26.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
19347574 COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS Non-Final OA Bexson Biomedical, Inc.
18008684 IMPROVED DEMINERALIZATION OF FERMENTATION BROTHS AND PURIFICATION OF FINE CHEMICALS SUCH AS OLIGOSACCHARIDES Final Rejection BASF SE
18468432 METHODS FOR ENHANCING CYTOTOXIC CANCER THERAPY THROUGH MODULATION OF PURINE BIOSYNTHESIS PATHWAYS Final Rejection Northwestern University
18043254 RNA STORAGE METHOD Non-Final OA KAO CORPORATION
18254488 POLYROTAXANE HAVING HYDROXY GROUP OR SULFO GROUP Non-Final OA NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
18245743 BIOMOLECULE EXTRACTION METHOD Non-Final OA NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM
17603908 METHOD AND KIT FOR THE PURIFICATION OF FUNCTIONAL RISC-ASSOCIATED SMALL RNAS Final Rejection ETH Zürich
18005943 PURIFICATION OF SULFONATED DNA Non-Final OA Exact Sciences Corporation
18009566 POLYSACCHARIDE COMPOSITIONS AND THERAPEUTIC GELS Non-Final OA The University of Birmingham
18268722 Pet Food Compositions Non-Final OA Hill's Pet Nutrition, Inc.
17986361 ORTHOESTER COMPOSITIONS FOR AFFINITY PURIFICATION OF OLIGONUCLEOTIDES Final Rejection Agilent Technologies, Inc.
18656010 ANIMAL MODELS, SCREENING METHODS, AND TREATMENT METHODS FOR INTRAOCULAR DISEASES OR DISORDERS Non-Final OA SMILEBIOTEK ZHUHAI LIMITED
17950520 2'-ALKYL OR 3'- ALKYL MODIFIED RIBOSE DERIVATIVES AND METHODS OF USE Non-Final OA Sanegene Bio USA Inc.
17789159 PHYSICAL MIX HA-COLLAGEN DERMAL FILLERS Non-Final OA ALLERGAN, INC.
18001429 CONJUGATE GROUP AND CONJUGATE Final Rejection MEDSHINE DISCOVERY INC.
18512636 COMPOSITIONS AND METHODS FOR TREATMENT OF MITOCHONDRIAL RESPIRATORY CHAIN DYSFUNCTION AND OTHER MITOCHONDRIAL DISORDERS Final Rejection THE CHILDREN'S HOSPITAL OF PHILADELPHIA
18504742 WOUND DRESSING COMPRISING HYALURONIC ACID-CALCIUM AND POLYLYSINE AND MANUFACTURING METHOD THEREFOR Non-Final OA YOUREH CO., LTD.
18278844 PHARMACEUTICAL COMPOSITION FOR TREATMENT OF NEUROINFLAMMATION, COMPRISING ELEUTHEROSIDE B AS ACTIVE INGREDIENT Non-Final OA YEP BIO CO. LTD.
18174111 FUNCTIONALIZED CELLULOSE NANOCRYSTALS STABILIZED SMART PICKERING EMULSION FOR ENHANCED PROBIOTIC DELIVERY Non-Final OA UNIVERSITY OF WATERLOO
18041642 USE OF A HEPARIN COMPOSITION IN THE TREATMENT OF VIRAL LUNG DISEASES, ACUTE AND/OR CHRONIC LUNG DISEASES BY SOFT MIST INHALER OR VIBRATION MESH TECHNOLOGY NEBULIZER THROUGH INHALATION ROUTE Non-Final OA ISTANBUL UNIVERSITESI REKTORLUGU
18020944 FISH SWIM BLADDER-DERIVED HEPARIN-LIKE MUCOPOLYSACCHARIDE AND METHODS OF MAKING AND USING THE SAME Non-Final OA SHENZHEN INSTITUTE OF GUANGDONG OCEAN UNIVERSITY
18007982 CANNABINOID-HYALURONIC ACID BIOCONJUGATES Non-Final OA LONDON PHARMACEUTICALS AND RESEARCH CORPORATION
17999910 COMPOUNDS FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF THROMBI Non-Final OA CARDIOVASCULAR LAB S.P.A
17924565 COMPATIBLE SOLUTES FOR PREVENTING OR TREATING SARS-COV-2 INFECTIONS Non-Final OA bitop AG
17916382 COMPOSITION AND METHOD FOR PRODUCING A COMPOSITION Final Rejection BIOPRONEO B.V.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month